AUPH News and Press, Aurinia Pharmaceuticals Inc From 06/25/21

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the Company) announced today that the Company’s licensing partner, Otsuka Pharmaceutical Europe Ltd. (OPEL), filed an initial Marketing Authorization Application (MAA) for voclosporin for the treatment of lupus nephritis...

The TSX today is filled with expensive stocks. Whereas last year we were in an economic downturn with cheap stocks galore, this year is different. Now the TSX trades at all-time highs, and most stocks are about the same with few Canadian stocks to buy cheap. In fact, the S&P 500 ...

When it comes to Bay Street, and investing in general, patience is what pays. You could look at the one-month performance of TSX stocks and see thousands of dollars lost. Or you could zoom out and see what those same shares have done over the last few years — even decades. People...

Lupkynis (voclosporin) received FDA approval in January 2021. Unwarranted sell-off after 1Q21 earnings release has created a buying opportunity. Anticipated solid Lupkynis revenue in 2Q21 and full year 2021. Doubling of share price achievable within 12 months. For furthe...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) announced today the appointment of Dr. Brinda Balakrishnan, M.D., Ph.D., to the Company’s Board of Directors effective June 14, 2021. Dr. Balakrishnan is Group Vice President, Corporate and Busine...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“ Aurinia ” or the “ Company ”) is pleased to announce that the eight incumbent directors of the Company were elected at the Company’s annual general meeting (the “ Meeting ...

- New examination of AURORA 1 Phase 3 data demonstrates increased renal response rates with LUPKYNIS™ (voclosporin) used in combination with MMF and low-dose steroids in patients with lupus nephritis regardless of target urine protein creatinine ratio (UPCR) - - The...

AUPH recently released long-term data for its lupus nephritis drug LUPKYNIS. It also hosted an earnings call to go over the first two months of sales data. I use all of this new information to revise my sales estimates and stock target price. For further details see: Aur...

The price of Aurnia's shares is currently at an inflection point. I expect to see LupKynis sales figures skyrocket in the coming quarters. Aurinia currently presents an excellent investment opportunity, with huge upside potential, for the coming months/years. For further det...

An interim analysis of Aurinia Pharmaceuticals' (AUPH) LUPKYNIS (voclosporin) for lupus sustained meaningful reductions in proteinuria with no change in mean estimated glomerular filtration rate at 104 weeks of treatment.The analysis of 216 blinded subjects found that proteinuria co...